33.64

0.65% -0.22

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $33.64, with a volume of 2.24M. It is down -0.65% in the last 24 hours and down -6.16% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Previous Close:

$33.86

Open:

$33.8

24h Volume:

2.24M

Relative Volume:

0.78

Market Cap:

$6.90B

Revenue:

$264.79M

Net Income/Loss:

$-14.36M

P/E Ratio:

-305.82

EPS:

-0.11

Net Cash Flow:

$-28.11M

1W Performance:

-22.56%

1M Performance:

-6.16%

6M Performance:

+16.77%

1Y Performance:

+98.82%

1-Day Range:

$33.45

$34.73

1-Week Range:

$33.15

$40.48

52-Week Range:

$15.16

$46.48

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

338

Twitter

@TGTherapeutics

Next Earnings Date

2025-03-03

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	33.64	6.90B	264.79M	-14.36M	-28.11M	-0.11
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

12:15 PM

Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus

12:15 PM

May 09, 2025